Dimeric 2G12 as a Potent Protection against HIV-1

English version České info

We previously showed that broadly neutralizing anti-HIV-1 antibody 2G12 (human IgG1) naturally forms dimers that are more potent than monomeric 2G12 in in vitro neutralization of various strains of HIV-1. In this study, we have investigated the protective effects of monomeric versus dimeric 2G12 against HIV-1 infection in vivo using a humanized mouse model. Our results showed that passively transferred, purified 2G12 dimer is more potent than 2G12 monomer at preventing CD4 T cell loss and suppressing the increase of viral load following HIV-1 infection of humanized mice. Using humanized mice bearing IgG “backpack” tumors that provided 2G12 antibodies continuously, we found that a sustained dimer concentration of 5–25 µg/ml during the course of infection provides effective protection against HIV-1. Importantly, 2G12 dimer at this concentration does not favor mutations of the HIV-1 envelope that would cause the virus to completely escape 2G12 neutralization. We have therefore identified dimeric 2G12 as a potent prophylactic reagent against HIV-1 in vivo, which could be used as part of an antibody cocktail to prevent HIV-1 infection.

Vyšlo v časopise: Dimeric 2G12 as a Potent Protection against HIV-1. PLoS Pathog 6(12): e32767. doi:10.1371/journal.ppat.1001225
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001225

Souhrn

Zdroje

1. PitisuttithumP

GilbertP

GurwithM

HeywardW

MartinM

2006 Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194 1661 1671

2. WatkinsDI

BurtonDR

KallasEG

MooreJP

KoffWC

2008 Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14 617 621

3. Rerks-NgarmS

PitisuttithumP

NitayaphanS

KaewkungwalJ

ChiuJ

2009 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 2209 2220

4. BurtonDR

StanfieldRL

WilsonIA

2005 Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102 14943 14948

5. MascolaJR

MontefioriDC

2010 The Role of Antibodies in HIV Vaccines. Annu Rev Immunol 28 413 444

6. TrkolaA

PurtscherM

MusterT

BallaunC

BuchacherA

1996 Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 1100 1108

7. ScanlanCN

PantophletR

WormaldMR

Ollmann SaphireE

StanfieldR

2002 The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol 76 7306 7321

8. CalareseDA

ScanlanCN

ZwickMB

DeechongkitS

MimuraY

2003 Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 2065 2071

9. CalareseDA

LeeHK

HuangCY

BestMD

AstronomoRD

2005 Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 102 13372 13377

10. BinleyJM

WrinT

KorberB

ZwickMB

WangM

2004 Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 13232 13252

11. BabaTW

LiskaV

Hofmann-LehmannR

VlasakJ

XuW

2000 Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6 200 206

12. MascolaJR

StieglerG

VanCottTC

KatingerH

CarpenterCB

2000 Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 207 210

13. HessellAJ

RakaszEG

PoignardP

HangartnerL

LanducciG

2009 Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5 e1000433

14. ArmbrusterC

StieglerGM

VcelarBA

JagerW

MichaelNL

2002 A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16 227 233

15. StieglerG

ArmbrusterC

VcelarB

StoiberH

KunertR

2002 Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16 2019 2025

16. TrkolaA

KusterH

RusertP

JoosB

FischerM

2005 Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11 615 622

17. MehandruS

VcelarB

WrinT

StieglerG

JoosB

2007 Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 81 11016 11031

18. JoosB

TrkolaA

KusterH

AcetoL

FischerM

2006 Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 50 1773 1779

19. BunnikEM

van GilsMJ

LobbrechtMS

PisasL

van NuenenAC

2009 Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Virology 390 348 355

20. WestAPJr

GalimidiRP

FoglesongCP

GnanapragasamPN

Huey-TubmanKE

2009 Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol 83 98 104

21. RochaB

TanchotC

2004 Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol 16 259 263

22. ZhangL

HeT

TalalA

WangG

FrankelSS

1998 In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 72 5035 5045

23. BaenzigerS

TussiwandR

SchlaepferE

MazzucchelliL

HeikenwalderM

2006 Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A 103 15951 15956

24. TraggiaiE

ChichaL

MazzucchelliL

BronzL

PiffarettiJC

2004 Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304 104 107

25. HanebergB

KendallD

ApterFM

NeutraMR

1997 Distribution of monoclonal antibodies in intestinal and urogenital secretions of mice bearing hybridoma ‘backpack’ tumours. Scand J Immunol 45 151 159

26. CarusoM

1996 Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Mol Med Today 2 212 217

27. Van DuyneR

PedatiC

GuendelI

CarpioL

Kehn-HallK

2009 The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 6 76

28. Dall'AcquaWF

WoodsRM

WardES

PalaszynskiSR

PatelNK

2002 Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169 5171 5180

29. ChallacombeSJ

RussellMW

1979 Estimation of the intravascular half-lives of normal rhesus monkey IgG, IgA and IgM. Immunology 36 331 338

30. ManriqueA

RusertP

JoosB

FischerM

KusterH

2007 In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 81 8793 8808

31. NakowitschS

QuendlerH

FeketeH

KunertR

KatingerH

2005 HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 19 1957 1966

32. ScanlanCN

PantophletR

WormaldMR

SaphireEO

CalareseD

2003 The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol 535 205 218

33. ZwickMB

WangM

PoignardP

StieglerG

KatingerH

2001 Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 75 12198 12208

34. MostoslavskyG

KottonDN

FabianAJ

GrayJT

LeeJS

2005 Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther 11 932 940

35. NaldiniL

BlomerU

GallayP

OryD

MulliganR

1996 In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 263 267